Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Neoadjuvant Treatment for Recurrent Meningioma
NCT04728568Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in meningioma, sponsored by Beijing Tiantan Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT04728568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728568.